Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNo. Wegovy (semaglutide) is not recommended during pregnancy. Clinical guidance from the NHS and the medicine's licensed information is clear: if you become pregnant while taking Wegovy, you should stop immediately and speak to your GP or midwife. The risks to the developing baby are not fully understood, and no prescription medicine for weight loss is considered appropriate during pregnancy without specialist guidance. This page sets out what is known, what remains uncertain, and who you should speak to in each scenario.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Stop taking Wegovy. That is the immediate, unambiguous step. The NHS medicines page for semaglutide and the medicine's own patient information leaflet both advise against use in pregnancy, and your prescriber, GP, or midwife will tell you the same. Wegovy is a prescription-only medicine; continuing it without reviewing your situation with a clinician is not appropriate.
Contact your GP or midwife as soon as you know you are pregnant. They will want to know when you last injected, review your overall health, and arrange any monitoring that is appropriate for your pregnancy. Most women find that their GP is able to see them promptly once pregnancy is confirmed, this is not a situation to sit on until a routine appointment becomes available.
It is worth understanding why the guidance is so firm on using Wegovy when pregnant, given that animal reproduction studies with semaglutide showed effects on foetal development, and while those findings do not translate directly to humans, there is simply not enough human safety data to say the medicine is safe during pregnancy. When data are absent, clinical guidance defaults to caution. The honest answer is that nobody knows the full picture, which is exactly why the licence excludes pregnancy.
Tell your prescriber or GP before you start trying to conceive. Both NHS England's guidance on weight-management injections and the medicine's licensed information recommend using effective contraception during Wegovy treatment, and stopping before attempting pregnancy. Semaglutide has a relatively long half-life; after your final injection it takes a number of weeks to clear your system fully. The NHS England weight-management injections page advises planning this washout period with your clinical team before discontinuing contraception.
The practical implication: if you are thinking about taking Wegovy when trying to get pregnant, you will need to plan ahead rather than simply stopping injections on the day you want to start trying. Your prescriber can advise on timing specific to your circumstances. We cannot set that interval here, it is a personal clinical conversation, not a fixed rule that applies identically to everyone.
For the semaglutide-specific picture on taking semaglutide during pregnancy more broadly, including the data behind the guidance, that page covers the evidence in detail.
Weight management during pregnancy is a matter for your midwife, GP, and obstetric team. Medicines licensed for weight loss in non-pregnant adults are not the tools used here. Your maternity team can advise on appropriate nutrition and activity during pregnancy, and if your BMI places you in a higher-risk group they will already be factoring that into your care plan.
Many people come to weight-loss services having already tried to manage weight through lifestyle changes for years, and questions about whether you can take Wegovy if you are pregnant are entirely understandable given how effective the medicine can be beforehand. Stopping Wegovy at the point of a positive pregnancy test can feel like a setback; it does not mean the treatment has failed, it means the clinical priorities have changed, and the right next step is a conversation with your maternity team about what support is available to you during pregnancy and postnatally.
Breastfeeding is also a period in which Wegovy is not recommended, and the broader question of whether you can take Wegovy while pregnant or in the period around birth comes down to the same reason of limited data, as it is not known whether semaglutide passes into breast milk in amounts that could affect a baby. The NHS semaglutide guidance is explicit on this point. Restarting any prescription weight-loss medicine after giving birth and finishing breastfeeding requires a fresh clinical review; circumstances change, and a prescriber needs to reassess your situation from the beginning.
If you are thinking about resuming treatment after that period, our Wegovy overview covers how the medicine works, what the clinical evidence shows, and what eligibility for a private prescription looks like. The free consultation is the right starting point, a GPhC-registered prescriber will review your current situation, not the one you were in before pregnancy. For questions in the meantime, the team is reachable via our contact page or the FAQs at the faqs page.
The MHRA Yellow Card scheme also allows patients to report any suspected side effects during or after pregnancy, which contributes to the ongoing safety monitoring of medicines like semaglutide.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.